Bitopertin

Drug Profile

Bitopertin

Alternative Names: R-1678; RG 6718; RG-6178; RG1678; RO-4917838

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antipsychotics; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Beta-thalassaemia
  • Discontinued Obsessive-compulsive disorders; Schizophrenia

Most Recent Events

  • 20 Oct 2017 Phase-II clinical trials in Beta-thalassaemia in Lebanon (PO), before October 2017 (NCT03271541)
  • 07 Sep 2017 Roche plans a phase II trial for Beta-thalassaemia in Lebanon (NCT03271541)
  • 01 Dec 2014 Roche completes a phase III trial in Schizophrenia in USA, Bulgaria, China, Czech Republic, Italy, Russia and Japan (NCT01235559; EudraCT2010-020718-26; WN25305)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top